CIDARA THERAPEUTICS INC (CDTX)
US1717571079 - Common Stock
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary...
Thursday's session: gap up and gap down stocks
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.
Get insights into the top gainers and losers of Thursday's pre-market session.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a great way to start Thursday as we check out all of the hottest news moving shares this morning!
Get insights into the top gainers and losers of Wednesday's after-hours session.
Get insights into the top gainers and losers of Wednesday's after-hours session.
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and...
Top movers in Wednesday's session
Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.
Let's take a look at the stocks that are in motion in today's session.
Which stocks are experiencing notable movement on Wednesday?
Traders are paying attention to the gapping stocks in Wednesday's session. Let's dive into which stocks are experiencing notable gaps.
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps.
Which stocks are moving after the closing bell on Tuesday?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023
CDTX stock results show that Cidara Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
CDTX Stock Earnings: Cidara Therapeutics Beats EPS, Beats Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cidara Therapeutics (NASDAQ:CDTX) just reported results for the fourth quarter ...
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary...
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary...
Which stocks are experiencing notable movement on Monday?
Top movers in Monday's session
Here are the top movers in Monday's session, showcasing the stocks with significant price changes.
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Cidara Therapeutics Announces Reverse Stock Split
SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary...
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study - CCR5-targeting DFC...
Cidara receives $11M milestone payment from partner Mundipharma (NASDAQ:CDTX)
Cidara (CDTX) said it has received an $11.14M milestone payment from partner Mundipharma related to the European approval of its antifungal drug Rezzayo. Read more here.
Cidara rallies 13% after hours on UK approval for Rezzayo (NASDAQ:CDTX)
Shares of Cidara Therapeutics (CDTX) rallied 13% in post-market trading Monday after the company said it had received UK regulatory approval for its drug Rezzay
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
The UK MHRA approval follows approvals by the U.S. FDA and the European CommissionCidara is entitled to receive a milestone payment of approximately $2.8...
Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
Approval based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive...
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
Top-line data expected in Q2 2024 SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology developing...
Cidara, Melinta announce publication of Rezzayo data in medical journal (NASDAQ:CDTX)
Shares of Cidara Therapeutics (CDTX) rose 7% after it announced publication of pooled data for Rezzayo in The Lancet Infectious Diseases. Read more here.
Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
Preclinical data on dual CD73/PD-1 targeting DFC to be presented for the first time...
Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting
SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform...
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted therapies...
Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)
The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and...
Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform...
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak®...
Cidara Therapeutics shares fall as chief scientific officer sells ~18K stock (NASDAQ:CDTX)
Cidara Therapeutics (CDTX) shares down 4.46% to $1.07 after the company disclosed on Sept
Cidara Therapeutics to Host Virtual Research & Development Day on its Cloudbreak® Development Pipeline on September 21, 2023
• Update on Phase 2a data for JNJ-0953 (CD388) for universal prevention of seasonal influenza from Janssen Pharmaceuticals, Inc. leadership following...
Cidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference
SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company using its proprietary...
Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now
While the very concept of penny stocks to buy is treacherous, these analyst-backed ideas could be enticing for the smart speculator.